Related references
Note: Only part of the references are listed.Short-term effect of low-dose rituximab on myasthenia gravis with muscle-specific tyrosine kinase antibody
Yufan Zhou et al.
MUSCLE & NERVE (2021)
Rituximab as induction therapy in refractory myasthenia gravis: 18month follow-up study
Nishita Singh et al.
JOURNAL OF NEUROLOGY (2019)
Stopping oral steroid-sparing agents at initiation of rituximab in myasthenia gravis
Ricardo H. Roda et al.
NEUROMUSCULAR DISORDERS (2019)
RITUXIMAB TREATMENT OF MYASTHENIA GRAVIS: A SYSTEMATIC REVIEW
Rup Tandan et al.
MUSCLE & NERVE (2017)
Rituximab as treatment for anti-MuSK myasthenia gravis Multicenter blinded prospective review
Michael K. Hehir et al.
NEUROLOGY (2017)
Resistant myasthenia gravis and rituximab: A monocentric retrospective study of 28 patients
Vadim Afanasiev et al.
NEUROMUSCULAR DISORDERS (2017)
PML in a patient with myasthenia gravis treated with multiple immunosuppressing agents
Kiran M. Kanth et al.
NEUROLOGY-CLINICAL PRACTICE (2016)
Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis
Raffaele Iorio et al.
JOURNAL OF NEUROLOGY (2015)
Characterization of B cells in muscle-specific kinase antibody myasthenia gravis
Jeffrey T. Guptill et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2015)
Long-lasting treatment effect of rituximab in MuSK myasthenia
J. Diaz-Manera et al.
NEUROLOGY (2012)
An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab
J Boye et al.
ANNALS OF ONCOLOGY (2003)
Share Paper
